DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/2ww7hq/pancreatic_cancer) has announced the addition of the "Pancreatic Cancer Drug Pipeline Update 2015" report to their offering.
There are today 291 companies plus partners developing 347 drugs targeting pancreatic cancer in development. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 128 drugs. Pancreatic Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 312 different targets.
All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 299 out of the 304 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.
All drugs targets are further categorized on in the software application by 70 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 14
- Registered - 1
- Pre-registration - 1
- Phase III - 26
- Phase II - 127
- Phase I - 91
- Preclinical - 82
- No Data - 5
- Suspended - 1
- Ceased - 128
For more information visit http://www.researchandmarkets.com/research/2ww7hq/pancreatic_cancer